Shares are $3.64 on more than 33 million in volume and closing in on 92,000 trades one hour after the open.
NeuroSense Therapeutics Reports Positive Preliminary Results from Novel Alzheimer’s Biomarker Study USA – English
CAMBRIDGE, Mass., June 30, 2022 /PRNewswire/ — NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense”), a company developing treatments for severe neurodegenerative diseases, today announced results from a biomarker study conducted to evaluate the potential of CogniC, NeuroSense’s combination drug for the treatment of Alzheimer’s disease (AD).